Your data on MRCVSonline
The nature of the services provided by Vision Media means that we might obtain certain information about you.
Please read our Data Protection and Privacy Policy for details.

In addition, (with your consent) some parts of our website may store a 'cookie' in your browser for the purposes of
functionality or performance monitoring.
Click here to manage your settings.
If you would like to forward this story on to a friend, simply fill in the form below and click send.

Your friend's email:
Your email:
Your name:
 
 
Send Cancel

African swine fever vaccine moves step closer
"It is very encouraging to see that the genes we have selected are able to protect pigs against ASF".
100 per cent of vaccinated pigs survive lethal dose of virus in a trial.

Scientists from the Pirbright Institute say they are 'one step closer' to finding a vaccine for African swine fever (ASF).

The announcement comes in response to a trial, in which 100 per cent of pigs vaccinated with the new vaccine survived a lethal dose of the ASF virus. The findings are published in the journal Vaccines.

The vaccine uses a non-harmful virus to deliver eight strategically selected genes from the ASF virus (ASFV) genome into pig cells. Once inside the cell, the genes produce viral proteins which prime the pig immune cells to respond to an ASF infection.

The trial showed that pigs immunised with the vaccine were protected from severe disease after challenge with an otherwise fatal strain of ASFV. However, some clinical signs of disease did develop.

“It is very encouraging to see that the genes we have selected are able to protect pigs against ASF,” commented Dr Chris Netherton, head of Pirbright’s ASF Vaccinology Group. “Although the pigs showed clinical signs of infection after challenge with the virus, our study has shown for the first time that a vectored vaccine against ASF is a realistic possibility.”

Researchers say this type of vaccine will also enable the differentiation of infected animals from those that have received a vaccine. This is important because it allows vaccination programmes to be established without sacrificing the ability to trade.

“Our next step will be to uncover the mechanisms behind how the proteins produced by the virus genes stimulate the immune system so we can refine and add to those included in the vaccine to improve effectiveness” added Dr Netherton.

Commenting on the findings, UK chief vet Christine Middlemiss said: “This is a very encouraging breakthrough and it means we are one step closer to safeguarding the health of our pigs and the wider industry’s role in global food supply from African swine fever.

"While there has never been an outbreak of African swine fever in the UK, we are not complacent and already have robust measures in place to protect against animal disease outbreaks."

Become a member or log in to add this story to your CPD history

FIVP launches CMA remedies survey

News Story 1
 FIVP has shared a survey, inviting those working in independent practice to share their views on the CMA's proposed remedies.

The Impact Assessment will help inform the group's response to the CMA, as it prepares to submit further evidence to the Inquiry Group. FIVP will also be attending a hearing in November.

Data will be anonymised and used solely for FIVP's response to the CMA. The survey will close on Friday, 31 October 2025. 

Click here for more...
News Shorts
CMA to host webinar exploring provisional decisions

The Competition and Markets Authority (CMA) is to host a webinar for veterinary professionals to explain the details of its provisional decisions, released on 15 October 2025.

The webinar will take place on Wednesday, 29 October 2025 from 1.00pm to 2.00pm.

Officials will discuss the changes which those in practice may need to make if the provisional remedies go ahead. They will also share what happens next with the investigation.

The CMA will be answering questions from the main parties of the investigation, as well as other questions submitted ahead of the webinar.

Attendees can register here before Wednesday, 29 October at 11am. Questions must be submitted before 10am on 27 October.

A recording of the webinar will be accessible after the event.